11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Topamac

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Topiramat

Topiramat

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Vovk T, Jakovljević MB, Kos MK, Janković SM, Mrhar A, Grabnar I. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biol Pharm Bull. 2010;33:1176-82.

  2. Sachdeo RC. Topiramate Clinical profile in epilepsy. Clin Pharmacokinet. 1998;34(5):335-46.

  3. Topiramate. DailyMed [www]. US National Library of Medicine. [updated 2023-05-15, cited 2024-01-19].

  4. Topimax (topiramat). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2022-05-31, cited 2024-01-19].

  5. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37 Suppl 6:S34-44.

  6. Yoo IH, Kim W, Kim H, Lim BC, Hwang H, Chae JH et al. Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients. J Clin Neurol. 2017;13(3):281-286.

  7. Alberici A, Borroni B, Manelli F, Griffini S, Zavarise P, Padovani A et al. Topiramate weight loss in migraine patients. J Neurol Sci. 2009;278:64-5.

  8. Reiter E, Feucht M, Hauser E, Freilinger M, Seidl R. Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients--a retrospective analysis. Seizure. 2004;13(7):491-3.

  9. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95:189-99.

  10. Sedighi B, Shafiei K, Azizpour I. Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients. Neurol Sci. 2016;37(4):585-9.

  11. PRAC recommends new measures to avoid topiramate exposure in pregnancy. European Medicines Agency (EMA) [www]. [updated 2023-09-01, cited 2024-01-19].

  12. Legato MJ, editor. Principles of Gender-Specific Medicine. Academic Press Inc; 2004.

  13. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14.

  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Vovk T, Jakovljević MB, Kos MK, Janković SM, Mrhar A, Grabnar I. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biol Pharm Bull. 2010;33:1176-82.
  2. Sachdeo RC. Topiramate Clinical profile in epilepsy. Clin Pharmacokinet. 1998;34(5):335-46.
  3. Topiramate. DailyMed [www]. US National Library of Medicine. [updated 2023-05-15, cited 2024-01-19].
  4. Topimax (topiramat). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2022-05-31, cited 2024-01-19].
  5. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37 Suppl 6:S34-44.
  6. Yoo IH, Kim W, Kim H, Lim BC, Hwang H, Chae JH et al. Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients. J Clin Neurol. 2017;13(3):281-286.
  7. Alberici A, Borroni B, Manelli F, Griffini S, Zavarise P, Padovani A et al. Topiramate weight loss in migraine patients. J Neurol Sci. 2009;278:64-5.
  8. Reiter E, Feucht M, Hauser E, Freilinger M, Seidl R. Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients--a retrospective analysis. Seizure. 2004;13(7):491-3.
  9. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95:189-99.
  10. Sedighi B, Shafiei K, Azizpour I. Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients. Neurol Sci. 2016;37(4):585-9.
  11. PRAC recommends new measures to avoid topiramate exposure in pregnancy. European Medicines Agency (EMA) [www]. [updated 2023-09-01, cited 2024-01-19].
  12. Legato MJ, editor. Principles of Gender-Specific Medicine. Academic Press Inc; 2004.
  13. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14.
  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]